Utilize este identificador para referenciar este registo: http://hdl.handle.net/10400.17/156
Título: Octreótido - Uma Terapêutica Opcional para Quilotórax Pós-Cirúrgico em Crianças com Cardiopatia Congénita
Outros títulos: Octreotide - Additional Conservative Therapy for Postoperative Chylothorax in Congenital Heart Disease
Autor: Paramés, F
Freitas, I
Fragata, J
Trigo, C
Pinto, MF
Palavras-chave: Criança
Quilotórax
Octreótido
Complicações Pós-Operatórias
Estudos Retrospectivos
Cardiopatia Congénita
Data: 2009
Editora: Sociedade Portuguesa de Cardiologia
Citação: Rev Port Cardiol. 2009 Jul-Aug;28(7-8):799-807
Resumo: INTRODUCTION: Chylothorax is a rare but serious postoperative condition in children with congenital heart disease. Conventional medical treatment consists of specific long-term dietary modification, and surgical reintervention, such as lymphatic duct ligation, may be indicated in refractory cases. In recent years, an additional conservative treatment, octreotide, a synthetic analog of somatostatin, has been used in management of congenital and postoperative chylothorax. METHODS: The objective of this work was to analyze the efficacy and safety of this treatment for chylothorax after congenital heart surgery. We reviewed the records of sixteen patients with chylothorax after surgery for congenital heart disease between January 1999 and December 2007, and collected the following data: demographic information; type of surgical procedure; onset, duration and management of chylothorax and treatment; and duration of hospital stay. To analyze efficacy we compared these parameters in children receiving conventional treatment only with those receiving octreotide. To analyze safety we compared the adverse effects of both treatments. Octreotide was administered at a dose of 4 to 10 microg/kg/hour, with monitoring of side effects. RESULTS: The incidence of chylothorax in our population was 1.6%. It occurred more often after Glenn and Fontan procedures (8 patients). Octreotide was begun three days after diagnosis of chylothorax and continued for a median of seventeen days (ranging from 4 to 26 days), until complete resolution. Side effects were frequent (in 3 of the 8 patients) but of no clinical relevance. All patients responded to the therapy and there was no indication for further surgical intervention. DISCUSSION AND CONCLUSIONS: Octreotide is safe and effective in the treatment of postoperative chylothorax in children with congenital heart disease. It is a useful adjunctive therapy to the conventional treatment of this complication.
URI: http://hdl.handle.net/10400.17/156
Aparece nas colecções:CCT - Artigos
CAR PED - Artigos

Ficheiros deste registo:
Ficheiro Descrição TamanhoFormato 
RPC 2009 799.pdf162,7 kBAdobe PDFVer/Abrir


FacebookTwitterDeliciousLinkedInDiggGoogle BookmarksMySpace
Formato BibTex MendeleyEndnote Degois 

Todos os registos no repositório estão protegidos por leis de copyright, com todos os direitos reservados.